Concepts (58)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 5 | 2017 | 170 | 0.620 |
Why?
|
| Oncology Nursing | 1 | 2011 | 5 | 0.350 |
Why?
|
| Nurse's Role | 1 | 2011 | 14 | 0.350 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 54 | 0.350 |
Why?
|
| Minority Groups | 1 | 2011 | 63 | 0.340 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 145 | 0.320 |
Why?
|
| Receptor, ErbB-2 | 2 | 2017 | 16 | 0.200 |
Why?
|
| Wnt3 Protein | 1 | 2017 | 4 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 55 | 0.130 |
Why?
|
| Survivors | 1 | 2014 | 15 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 49 | 0.110 |
Why?
|
| Female | 5 | 2017 | 4060 | 0.100 |
Why?
|
| Nurse-Patient Relations | 1 | 2011 | 3 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 23 | 0.090 |
Why?
|
| Patient Selection | 1 | 2011 | 40 | 0.090 |
Why?
|
| Patient Participation | 1 | 2011 | 32 | 0.090 |
Why?
|
| California | 1 | 2011 | 230 | 0.080 |
Why?
|
| Humans | 5 | 2017 | 6794 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 27 | 0.070 |
Why?
|
| Amino Acid Transport Systems | 1 | 2006 | 1 | 0.060 |
Why?
|
| Amino Acids | 1 | 2006 | 15 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 6 | 0.060 |
Why?
|
| Paclitaxel | 1 | 2006 | 14 | 0.060 |
Why?
|
| Apoptosis | 1 | 2006 | 179 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 156 | 0.050 |
Why?
|
| Thiosemicarbazones | 1 | 2017 | 2 | 0.030 |
Why?
|
| Twist-Related Protein 1 | 1 | 2017 | 2 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 3 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2017 | 6 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2017 | 11 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 15 | 0.030 |
Why?
|
| beta Catenin | 1 | 2017 | 15 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2017 | 13 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 17 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 30 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 88 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 5 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 38 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 28 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 24 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 118 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 95 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 2 | 0.020 |
Why?
|
| Ethylmaleimide | 1 | 2006 | 2 | 0.020 |
Why?
|
| Maleimides | 1 | 2006 | 5 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2006 | 5 | 0.020 |
Why?
|
| Starvation | 1 | 2006 | 3 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2006 | 9 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 12 | 0.020 |
Why?
|
| Alanine | 1 | 2006 | 4 | 0.020 |
Why?
|
| Caspases | 1 | 2006 | 29 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 53 | 0.020 |
Why?
|
| Sodium | 1 | 2006 | 43 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 155 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 120 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2006 | 143 | 0.010 |
Why?
|
| African Americans | 1 | 2008 | 264 | 0.010 |
Why?
|
| Middle Aged | 1 | 2008 | 2108 | 0.010 |
Why?
|